- Home
- BIRD vs CRVO Comparison
BIRD vs CRVO Comparison
Compare BIRD & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | CRVO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 25.9M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BIRD | CRVO |
|---|---|---|
| Price | $2.39 | $2.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $8.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 604.5K | 151.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $2.13 |
| 52 Week High | $24.31 | $10.00 |
Technical Indicators
Market Signals| Indicator | BIRD | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 39.76 |
| Support Level | $2.22 | $2.13 |
| Resistance Level | $2.71 | $3.20 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 46.97 | 9.26 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.